1. Introduction
Centralized drug bidding and procurement refers to a procurement method in which multiple medical institutions purchase the required drugs in the form of bidding through a centralized drug bidding and procurement organization.
The purpose of centralized drug bidding and procurement is to ensure the smooth implementation of the basic medical insurance system for urban employees, to control unhealthy practices in the purchase and sale of medicines from the source, to standardize the purchase and sale of medicines in medical institutions, and to reduce the burden of medical expenses on society.
On February 3, 2021, the bids for the fourth batch of nationally organized drug centralized procurement were opened in Shanghai, and the results of the proposed selection were produced. This procurement resulted in 118 companies to be selected, and 158 products to be selected. The average price of the products to be selected was reduced by 52%.
2. Procurement information
The scope of centralized drug bidding and procurement generally covers clinically used drugs for basic medical services for urban employees. Drugs that are routinely used and used in large quantities must be subject to centralized bidding and procurement.
Centralized bidding and procurement of drugs should follow the principles of safety first, quality first, price consideration, straightening out channels, step-by-step implementation, and gradual promotion. It should not only comply with laws and regulations on pharmaceutical management, but also be consistent with reality, so as to standardize drug purchase and sales behavior. To serve the general public.
In August 2020, the third batch of centralized procurement of state-organized drugs with a procurement scale of tens of billions of yuan produced the results of the proposed selection. The announcement period ended on the 23rd, and many star drugs have given "jumping prices".
A total of 189 companies participated in this procurement, with 125 companies to be selected and 191 products to be selected. The average price reduction of the products to be selected was 53%, with a maximum reduction of 95%. From the perspective of drug types, 56 varieties are planned to be included, involving more than 300 product specifications, and the types of diseases treated include malignant tumors, hypertension, diabetes, mental diseases, etc.